Adial Pharmaceuticals (ADIL) said Monday it has locked database for its phase 3 study of AD04 in patients with alcohol use disorder and selected...
Adial Pharmaceuticals (ADIL) said Tuesday that it secured a new patent in the US covering the combined use of its genetic diagnostic panel with its lead...
Adial Pharmaceuticals (ADIL) said Thursday its Purnovate unit has entered into a research partnership with the Medical College of Wisconsin. The...
Adial Pharmaceuticals (ADIL) said Wednesday its Purnovate unit has entered into a research collaboration agreement with the University of California San...
| Address | 1180 Seminole Trail Charlottesville, Virginia 22901 |
| Phone | +1.434.422.9800 |
| Number of Employees | N/A |
| Recent SEC Filing | 06/29/2022 EFFECT |
| President, Chief Executive Officer & Director | William B. Stilley |
| Chief Operating Officer & Director | Cary J. Claiborne |
| Chief Financial Officer, Secretary & Treasurer | Joseph Truluck |
| Chief Medical Officer | Bankole A. Johnson |
| Price Open | $1.34 |
| Previous Close | $1.34 |
| 52 Week Range | $1.04 - 5.08 |
| Market Capitalization | $28.5 M |
| Shares Outstanding | 23.8 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/11/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.82 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -266.69% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
